Rezurock and Peripheral swelling - a phase IV clinical study of FDA data

Summary:

Peripheral swelling is reported as a side effect among people who take Rezurock (belumosudil mesylate), especially for people who are male, 60+ old, also take Jakafi, and have Chronic graft versus host disease.

The phase IV clinical study analyzes which people have Peripheral swelling when taking Rezurock. It is created by eHealthMe based on reports of 1,132 people who have side effects when taking Rezurock from the FDA, and is updated regularly.

What is Rezurock?

Rezurock has active ingredients of belumosudil mesylate. eHealthMe is studying from 1,132 Rezurock users. Check the latest studies of Rezurock.

What is Peripheral swelling?

Peripheral swelling is found to be associated with 2,183 drugs and 1,743 conditions by eHealthMe. Check the latest studies of Peripheral swelling.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

1,132 people reported to have side effects when taking Rezurock.
Among them, 17 people (1.5%) have Peripheral swelling.

Could Rezurock cause Peripheral swelling?

Among these 17 people:

What is the gender of people who have Peripheral swelling when taking Rezurock? *

female: 46.67 %
male: 53.33 %

What is the age of people who have Peripheral swelling when taking Rezurock? *

What are other drugs people take besides Rezurock? *

What are other side effects people have besides Peripheral swelling? *

Hypoaesthesia (reduced sense of touch or sensation): 3 people, 17.65%
Dizziness: 3 people, 17.65%
Balance Disorder: 2 people, 11.76%
Feeling Abnormal: 2 people, 11.76%
Recurrent Cancer (repeated cancer): 2 people, 11.76%
Burning Sensation: 2 people, 11.76%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 2 people, 11.76%
Fatigue (feeling of tiredness): 2 people, 11.76%
Orthostatic Hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up): 2 people, 11.76%
Insomnia (sleeplessness): 2 people, 11.76%

What are the existing conditions these people have? *

Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 8 people, 47.06%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 4 people, 23.53%
Nausea (feeling of having an urge to vomit): 1 person, 5.88%
Muscle Aches (muscle pain): 1 person, 5.88%
Fever: 1 person, 5.88%
Fatigue (feeling of tiredness): 1 person, 5.88%
Diarrhea: 1 person, 5.88%
Bone Pain: 1 person, 5.88%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 5.88%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Rezurock and have Peripheral swelling?

- Check whether Peripheral swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rezurock:

Rezurock (1,132 reports)

Browse all side effects of Rezurock:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral swelling:

Peripheral swelling (2,183 drugs)

Browse all the conditions that are associated with Peripheral swelling:

Peripheral swelling (1,743 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on belumosudil mesylate (the active ingredients of Rezurock) and Rezurock (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.